U827, Inserm Montpellier, F-34000, France ; Univ, Montpellier I Montpellier, F-34000, France.
U827, Inserm Montpellier, F-34000, France ; Grupo de Investigación en Enfermedades Neurosensoriales, Instituto de Investigación Sanitaria IIS-La Fe and CIBERER Valencia, Spain.
Mol Genet Genomic Med. 2014 Jan;2(1):30-43. doi: 10.1002/mgg3.25. Epub 2013 Jul 10.
We show that massively parallel targeted sequencing of 19 genes provides a new and reliable strategy for molecular diagnosis of Usher syndrome (USH) and nonsyndromic deafness, particularly appropriate for these disorders characterized by a high clinical and genetic heterogeneity and a complex structure of several of the genes involved. A series of 71 patients including Usher patients previously screened by Sanger sequencing plus newly referred patients was studied. Ninety-eight percent of the variants previously identified by Sanger sequencing were found by next-generation sequencing (NGS). NGS proved to be efficient as it offers analysis of all relevant genes which is laborious to reach with Sanger sequencing. Among the 13 newly referred Usher patients, both mutations in the same gene were identified in 77% of cases (10 patients) and one candidate pathogenic variant in two additional patients. This work can be considered as pilot for implementing NGS for genetically heterogeneous diseases in clinical service.
我们表明,针对 19 个基因的大规模平行靶向测序为乌谢尔综合征(USH)和非综合征性耳聋的分子诊断提供了一种新的、可靠的策略,特别是对于这些以高度临床和遗传异质性以及涉及的几个基因的复杂结构为特征的疾病。研究了一系列包括先前通过桑格测序筛选的乌谢尔患者和新转诊患者的 71 名患者。通过下一代测序(NGS)发现了 98%的先前通过桑格测序鉴定的变异。NGS 被证明是有效的,因为它可以分析所有相关基因,而这是桑格测序难以达到的。在 13 名新转诊的乌谢尔患者中,相同基因中的两种突变在 77%的病例(10 名患者)中被鉴定出来,另外两名患者中有一个候选致病性变异。这项工作可以被认为是在临床服务中对遗传异质性疾病实施 NGS 的试点。